The top 10 best-selling drugs of the first quarter of 2023 generated total revenues of $33.0bn, down from $46.3bn a year earlier.
Top 10 Best-Selling Drugs Of Q1 2023: Keytruda Topples Humira
COVID-19 Products And Humira Decline As Keytruda Continues Ascent
A review of the top-selling drugs of the first quarter of 2023 demonstrate the declining turnover from products to treat or prevent COVID-19, as well as a precipitative drop by Humira. Merck & Co’s PD-1 inhibitor Keytruda grew strongly, and Novo Nordisk’s injectable diabetes drug Ozempic burst into the top 10 ranks.
More from Earnings
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.